Kali Therapeutics announced a licensing agreement with Sanofi (NASDAQ: SNY) for KT501, a novel trispecific T-cell engager (TCE) targeting CD3, CD19, and BCMA for the treatment of B-cell-mediated autoimmune diseases. The deal provides Sanofi with exclusive global rights and Kali with $180 million upfront and near-term payments, plus up to $1.05 billion in milestones and tiered royalties (high single digits to double digits).
Novartis (TCE in SLE), Roche (CD19-TCB), Johnson & Johnson (talquetamab in autoimmunity); KT501’s trispecificity differentiates
Market Size
$50+ billion addressable across B-cell autoimmunity; TCEs could capture $5–10 billion with superior efficacy vs. biologics
Development Timeline: Sanofi to initiate Phase I autoimmune trials 2026–2027; indication selection based on B-cell depletion depth and safety profile
Commercial Potential: Peak sales $2–4 billion globally if approved in multiple autoimmune indications with best-in-class B-cell depletion
Forward‑Looking Statements This brief contains forward‑looking statements regarding milestone achievement, clinical development progress, and commercial potential for KT501 in autoimmune diseases. Actual results may differ due to TCE toxicities (cytokine release syndrome, neurotoxicity), competitive dynamics in the autoimmune TCE space, and reimbursement challenges for high-cost biologics in chronic diseases.-Fineline Info & Tech
By Fineline Cube